0
December 7, 1970, Vol 214, No. 10 >
ARTICLE | December 7, 1970

Treatment of Atrial Arrhythmias With Alprenolol FREE

Richard E. Kerber, MD; Robert H. Goldman, MD; Ralph E. Gianelly, MD; Donald C. Harrison, MD
[+] Author Affiliations

Read before the American Federation

for Clinical Research, Carmel, Calif, Jan 29,1970.

Reprint requests to Cardiology Division, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, Calif 94305 (Dr. Harrison).


JAMA. 1970;214(10):1849-1854. doi:10.1001/jama.1970.03180100043008
Text Size: A A A
Published online
Article
References

Alprenolol (Aptine), a new beta-adrenergic blocking agent, was administered intravenously on 25 occasions to 23 patients with atrial arrhythmias. Significant slowing of ventricular rate was achieved in 20 patients by decreasing atrioventricular conduction in atrial fibrillation and flutter, and by slowing of the rate of ectopic impulse formation in paroxysmal supraventricular tachycardia. Four patients with the latter arrhythmia reverted to sinus rhythm following alprenolol administration. In four patients with atrial fibrillation, the chronotropic effect of isoproterenol was substantially abolished after treatment with alprenolol. Alprenolol appears to be a safe and effective beta-adrenergic blocking agent in the treatment of atrial arrhythmias.

REFERENCES

1 +
Anzola J, Rushmer RF:  Cardiac response to sympathetic stimulation . Circ Res 4:302-307, 1956;.
2 +
Randall WC, McNally H:  Augmentor action of the sympathetic cardiac nerves in man . J Appl Physiol 15:629-631, 1960;.
3 +
Mendez C, Aceves J, Mendez R:  Antiadrenergic action of digitalis on the refractory period of the A-V transmission system . J Pharmacol Exp Ther 131:199-204, 1961;.
4 +
Kahler RL, Gaffney TE,  Braunwald E: Effects of autonomic nervous system inhibition on the circulatory response to muscular exercise . J Clin Invest 41:1981-1987, 1962;.
5 +
Ahlquist RP:  A study of the adrenotropic receptors . Amer J Physiol 153:586-599, 1948;.
6 +
Linhart JW, Braunwald E, Ross J:  Determinants of the duration of the refractory period of the atrioventricular nodal system in man . J Clin Invest 44: 883-890, 1965;.
7 +
Powell CE, Slater IH:  Blocking of inhibitory adrenergic receptors by dichloro analog of isoproterenol . J Pharmacol Exp Ther 122:480-491, 1958;.
8 +
Gianelly R, Griffin JR, Harrison DC:  Propranolol in the treatment and prevention of cardiac arrhythmias . Ann Intern Med 66:667-676, 1967;.
9 +
Berkowitz WD, Wit AL, Lau SH, et al:  The effects of propranolol on cardiac conduction . Circulation 40:855-862, 1969;.
10 +
Johnson G, Norrby A, Solvell L:  Potency and time-effect relationship in man of propranolol and H 56/28: I. Comparative studies after intravenous administration . Acta Pharmacol 25 ( (suppl 2) ):95-105, 1967;.
11 +
Ablad B, Brogard M, and Ak L:  Pharmacological properties of H 56/28 a beta-adrenergic receptor antagonist . Acta Pharmacol 25 ( (suppl 2) ): 9-40, 1967;.
12 +
Forsberg SA, Johnson G:  Hemodynamic effects of propranolol and H 56/28 in man . Acta Pharmacol 25 ( (suppl 2) ):75-83, 1967;.
13 +
Lund-larssen PG, Sivertssen E:  Hemodynamic effects of propranolol (Inderal) and H 56/28 (Aptin) in patients with acute myocardial infarction . Acta Med Scand 186:187-191, 1969;.
14 +
Wasserman AJ, Proctor JD, Allen FJ et al:  Human cardiovascular effects of alprenolol, a beta-adrenergic blocker: Hemodynamic, antiarrhythmic, and anginal . J Clin Pharmacol 10:37-49, 1970;.
15 +
Lown B, Ganong WF, Levine SA:  The syndrome of short P-R interval, normal QRS complex and paroxysmal rapid heart action . Circulation 5:693-706, 1952;.
16 +
Sekiya A, Vaughn Williams EM:  A comparison of the antifibrillatory action and effects on intracellular cardiac potentials of pronethalol, disopyramide and quinidine . Brit J Pharmacol 21:473-481, 1963;.
17 +
Parmely WW, Braunwald E:  Comparative myocardial depressant and antiarrhythmic properties of propranolol, dlpropranolol and quinidine . J Pharmacol Exp Ther 158:11-21, 1967;.
18 +
Howe R, Shanks RH:  Optical isomers of propranolol Nature 210:1336-1338, 1966;.
19 +
Duce BR, Garberg L, Johansson B:  Effect of propranolol and the dextro and laevo isomers of H 56/28 on ouabain-induced ventricular tachycardia in unanesthetized dogs . Acta Pharmacol 25: ( (suppl 2) ): 41-49, 1967;.
20 +
Lord CO, Katz RL, Eahrins KE:  Antiarrhythmic properties of stereoisomers of a beta adrenergic blocking agent (H 56/28) . Anesthesiology 29:288-294, 1968;.
21 +
Linko E, Siitonen L, Ruosteenoja R:  A new beta-adrenergic receptor blocking agent, H 56/28, in the treatment of cardiac arrhythmias . Acta Med Scand 181: 547-555, 1967;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Anzola J, Rushmer RF:  Cardiac response to sympathetic stimulation . Circ Res 4:302-307, 1956;.
2 +
Randall WC, McNally H:  Augmentor action of the sympathetic cardiac nerves in man . J Appl Physiol 15:629-631, 1960;.
3 +
Mendez C, Aceves J, Mendez R:  Antiadrenergic action of digitalis on the refractory period of the A-V transmission system . J Pharmacol Exp Ther 131:199-204, 1961;.
4 +
Kahler RL, Gaffney TE,  Braunwald E: Effects of autonomic nervous system inhibition on the circulatory response to muscular exercise . J Clin Invest 41:1981-1987, 1962;.
5 +
Ahlquist RP:  A study of the adrenotropic receptors . Amer J Physiol 153:586-599, 1948;.
6 +
Linhart JW, Braunwald E, Ross J:  Determinants of the duration of the refractory period of the atrioventricular nodal system in man . J Clin Invest 44: 883-890, 1965;.
7 +
Powell CE, Slater IH:  Blocking of inhibitory adrenergic receptors by dichloro analog of isoproterenol . J Pharmacol Exp Ther 122:480-491, 1958;.
8 +
Gianelly R, Griffin JR, Harrison DC:  Propranolol in the treatment and prevention of cardiac arrhythmias . Ann Intern Med 66:667-676, 1967;.
9 +
Berkowitz WD, Wit AL, Lau SH, et al:  The effects of propranolol on cardiac conduction . Circulation 40:855-862, 1969;.
10 +
Johnson G, Norrby A, Solvell L:  Potency and time-effect relationship in man of propranolol and H 56/28: I. Comparative studies after intravenous administration . Acta Pharmacol 25 ( (suppl 2) ):95-105, 1967;.
11 +
Ablad B, Brogard M, and Ak L:  Pharmacological properties of H 56/28 a beta-adrenergic receptor antagonist . Acta Pharmacol 25 ( (suppl 2) ): 9-40, 1967;.
12 +
Forsberg SA, Johnson G:  Hemodynamic effects of propranolol and H 56/28 in man . Acta Pharmacol 25 ( (suppl 2) ):75-83, 1967;.
13 +
Lund-larssen PG, Sivertssen E:  Hemodynamic effects of propranolol (Inderal) and H 56/28 (Aptin) in patients with acute myocardial infarction . Acta Med Scand 186:187-191, 1969;.
14 +
Wasserman AJ, Proctor JD, Allen FJ et al:  Human cardiovascular effects of alprenolol, a beta-adrenergic blocker: Hemodynamic, antiarrhythmic, and anginal . J Clin Pharmacol 10:37-49, 1970;.
15 +
Lown B, Ganong WF, Levine SA:  The syndrome of short P-R interval, normal QRS complex and paroxysmal rapid heart action . Circulation 5:693-706, 1952;.
16 +
Sekiya A, Vaughn Williams EM:  A comparison of the antifibrillatory action and effects on intracellular cardiac potentials of pronethalol, disopyramide and quinidine . Brit J Pharmacol 21:473-481, 1963;.
17 +
Parmely WW, Braunwald E:  Comparative myocardial depressant and antiarrhythmic properties of propranolol, dlpropranolol and quinidine . J Pharmacol Exp Ther 158:11-21, 1967;.
18 +
Howe R, Shanks RH:  Optical isomers of propranolol Nature 210:1336-1338, 1966;.
19 +
Duce BR, Garberg L, Johansson B:  Effect of propranolol and the dextro and laevo isomers of H 56/28 on ouabain-induced ventricular tachycardia in unanesthetized dogs . Acta Pharmacol 25: ( (suppl 2) ): 41-49, 1967;.
20 +
Lord CO, Katz RL, Eahrins KE:  Antiarrhythmic properties of stereoisomers of a beta adrenergic blocking agent (H 56/28) . Anesthesiology 29:288-294, 1968;.
21 +
Linko E, Siitonen L, Ruosteenoja R:  A new beta-adrenergic receptor blocking agent, H 56/28, in the treatment of cardiac arrhythmias . Acta Med Scand 181: 547-555, 1967;.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems